• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

NeoDynamics

Less than 1K followers

NeoDynamics AB (publ) is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of breast cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden.

Read more
Coverage
Disclaimer
All
Research
Webcasts
Press releases
ShowingAll content types

Press release30.07.2024 klo 12.00

Last day of trading at Nasdaq First North

NeoDynamics
Regulatory press release12.07.2024 klo 09.59

Unofficial trading through Pareto Securities after delisting

NeoDynamics
Regulatory press release03.07.2024 klo 11.15

NeoDynamics terminates the agreement with liquidity provider

NeoDynamics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release02.07.2024 klo 14.48

NeoDynamics' stock is delisted from Nasdaq First North

NeoDynamics
Regulatory press release20.06.2024 klo 19.00

NeoDynamics applies for delisting

NeoDynamics
Regulatory press release17.06.2024 klo 18.45

Bulletin from the annual general meeting in NeoDynamics AB (publ)

NeoDynamics
Regulatory press release04.06.2024 klo 23.00

Update on NeoDynamics’ financial situation

NeoDynamics
Regulatory press release15.05.2024 klo 22.55

NOTICE OF ANNUAL GENERAL MEETING IN NEODYNAMICS AB (PUBL)

NeoDynamics
Regulatory press release15.05.2024 klo 22.45

NeoDynamics intends to apply for delisting

NeoDynamics
Regulatory press release07.05.2024 klo 09.45

NeoDynamics Interim Report Jan-March 2024

NeoDynamics
Regulatory press release01.05.2024 klo 09.00

NeoDynamics publishes Annual Report 2023

NeoDynamics
Press release25.04.2024 klo 17.30

Update on NeoDynamics’ management team

NeoDynamics
Press release15.04.2024 klo 09.45

Salénterprise increases its shareholding in NeoDynamics.

NeoDynamics
Regulatory press release04.04.2024 klo 12.30

NeoDynamics announces the final outcome regarding the exercise warrants of series TO3

NeoDynamics
Regulatory press release22.03.2024 klo 09.45

Update on NeoDynamics’ Management Team

NeoDynamics
Regulatory press release20.03.2024 klo 09.45

NeoDynamics announces outcome of RIghts issue of shares

NeoDynamics
HCA Biosnack update: Biotech and Life Science stocks outperform as the general stock market moves to record highs.
Analyst Comment14.03.2024 klo 10.36

HCA Biosnack update: Biotech and Life Science stocks outperform as the general stock market moves to record highs.

After a slow start to 2024, February and the beginning of March turned out to be a very strong period for Biotech and Life Science stocks as illustrated above. Even more so, if measured since late October 2023. Looking at 2024, the general S&P Biotech index is now up 7.7 percent year-to-date, outperforming MSCI World All Countries which is up 7.0 percent. Nordic focused HCA Little Mermaid index is up 6.0 percent.

Ascelia PharmaBioPortoCurasightExpreS2ion BiotechFluoGuideNeoDynamicsPharma Equity GroupQlife Holding
Regulatory press release07.03.2024 klo 09.45

NeoDynamics announces the preliminary outcome of the exercise of warrants of series TO3.

NeoDynamics
Regulatory press release29.02.2024 klo 14.00

Update on NeoDynamics’ Management Team

NeoDynamics
Regulatory press release29.02.2024 klo 10.40

Correction of press release: NeoDynamics publishes information memorandum in connection with the forthcoming rights issue

NeoDynamics